Palvella Therapeutics (PVLA) Operating Expenses (2013 - 2026)

Palvella Therapeutics (PVLA) has reported Operating Expenses for 14 consecutive years, with $14.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Expenses rose 88.73% year-over-year to $14.9 million; the TTM figure through Mar 2026 stood at $45.6 million (up 125.6% YoY), while the FY2025 annual figure was $38.6 million, up 173.87% from the prior year.
• Operating Expenses improved to $14.9 million in Q1 2026 per PVLA's latest filing, from $11.3 million in the prior quarter.
• Across five years, Operating Expenses topped out at $31.3 million in Q3 2023 and bottomed at -$54.9 million in Q4 2023.
• Historically, Operating Expenses has averaged $8.8 million across 5 years, with a median of $11.3 million in 2025.
• Annual changes were most pronounced in 2023 — Operating Expenses tumbled 416.14% — and 2025, when it surged 347.47%.
• Palvella Therapeutics' Operating Expenses stood at $17.4 million in 2022, then sank by 416.14% to -$54.9 million in 2023, then jumped by 107.95% to $4.4 million in 2024, then jumped by 158.91% to $11.3 million in 2025, then soared by 31.41% to $14.9 million in 2026.
• Business Quant data shows PVLA's Operating Expenses at $14.9 million in Q1 2026, $11.3 million in Q4 2025, and $10.2 million in Q3 2025.